NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Valneva SE (VALN) Stock Analysis

Valneva SE (VALN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

VALN

$6.89

−$0.17 (−2.41%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VALN with… →

VALN Key Statistics

As of Sep 4, 2026
Trading
Open
$6.92
Previous Close
$7.06
Day's Range
6.87–7.00
52-Week Range
4.75–12.23
Volume
22.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.37
Valuation
Market Cap
$653.33M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
5.79
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.57
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.08
Financials (FY)
Revenue (FY)
$174.66M+3.00%
Net Income (FY)
−$115.19M
Profit marginThe share of revenue left as profit after all costs and taxes.
−110.29%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
94.82M
1-Year Return
−22.06%
Dividend and dates
Avg Volume
76.75K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

VALN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−21.88%
2025+101.74%
2024−57.84%
2023−18.48%
2022−77.09%
2021 (partial year)+110.19%

As of September 4, 2026.

VALN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$174.66M−$115.19M−66.0%
2024$169.58M−$12.25M−7.2%
2023$153.71M−$101.43M−66.0%
2022$361.30M−$143.28M−39.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$174.66M$67.52M−$81.63M−$115.19M−66.0%
2024$169.58M$71.04M−$77.77M−$12.25M−7.2%
2023$153.71M$52.84M−$82.11M−$101.43M−66.0%
2022$361.30M$36.86M−$113.44M−$143.28M−39.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

VALN Valuation vs Biotechnology Median

Median of 656 stocks
MetricVALNBiotechnology medianvs median
P/S ratio4.5715.260.3x the median
Profit margin−110.29%0.00%110.3 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Valneva SE (VALN) carries a market capitalisation of $653.33M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 620.

The most recent close on file for VALN is $6.89, dated September 4, 2026. That is −$0.17 (−2.41%) against the previous close. Over the past 52 weeks the price has ranged from $4.75 to $12.23. The latest close sits 45.05% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $174.66M. That is +3.00% against the prior fiscal year, when revenue was $169.58M. The same year closed with a net loss of $115.19M. Profit margin runs at −110.29%. That is 110.3 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −2.08.

Across the 4 fiscal years on file, revenue moves from $361.30M in 2022 to $174.66M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 5.79. Measured against sales, the shares trade at 4.57 times revenue. On price-to-sales that is 0.3 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned −22.06%. Across 5 years the annualized return works out at −32.14%. The reported beta is 1.37. Annualized volatility over the trailing 5 years is 92.82%.

Growth & Income

No dividend is on file for VALN.

The strongest complete calendar year on file is 2025 at +101.74%; the weakest is 2022 at −77.09%. Of the 4 complete calendar years on file, 1 finished higher. 2026 is still running; the price is −21.88% year to date.

Peer Comparison

Valneva SE (VALN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Valneva SE VALN $653.33M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Valneva SE has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Valneva SE

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; PF-07307405, a vaccine candidate to prevent Lyme disease cases in individuals aged five years and older and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.

Visit website →